

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
9 September 2005 (09.09.2005)

PCT

(10) International Publication Number  
**WO 2005/082934 A3**

(51) International Patent Classification<sup>7</sup>: **C07K 14/47**,  
C12N 15/63, 15/79, 15/85, C07K 16/24, A61K 38/00,  
39/00

(74) Agents: **GARRETT, Arthur, S.** et al.; Finnegan, Hender-  
son, Farabow, Garrett & Dunner, LLP, 901 New York Av-  
enue, N.W., Washington, D.C. 20005 (US).

(21) International Application Number:  
PCT/US2005/005221

(22) International Filing Date: 18 February 2005 (18.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/546,385 20 February 2004 (20.02.2004) US  
60/647,013 27 January 2005 (27.01.2005) US  
60/654,229 18 February 2005 (18.02.2005) US

(71) Applicant (for all designated States except US): **FIVE  
PRIME THERAPEUTICS, INC.** [US/US]; 951 Gateway  
Boulevard, South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WANG, Yan**  
[CN/CN]; 1075 Park Place #306, San Mateo, CA 94403  
(US). **COLLINS, Amy, L., Tsui** [US/US]; 5955 Girvin  
Drive, Oakland, CA 94611 (US). **HESTIR, Kevin**  
[US/US]; 226 Arlington Avenue, Kensington, CA 94707  
(US). **LEE, Ernestine** [US/US]; 226 Arlington Avenue,  
kensington, CA 94707 (US). **HALENBECK, Robert,**  
**Forgan** [US/US]; 59 Golden Hinde Blvd., San Rafael, CA  
94903 (US). **BOSCH, Elizabeth** [US/US]; 23047 Cricket  
Hill Road, Cupertino, CA 95014 (US). **LINNEMANN,**  
**Thomas** [DE/US]; 1338 Baker Street #7, San Francisco,  
CA 94115 (US). **WILLIAMS, Lewis, T.** [US/US]; 125  
Chapel Drive, Mill Valley, CA 94941 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,  
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,  
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(88) Date of publication of the international search report:  
15 December 2005

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: NOVEL APO2L AND IL-24 POLYPEPTIDES, POLYNUCLEOTIDES, AND METHODS OF THEIR USE

(57) Abstract: Disclosed are newly identified Interleukin 24 and APO2L splice variant molecules, their polypeptide sequences, and the polynucleotides encoding the polypeptide sequences. Also provided is a procedure for producing such polypeptides by recombinant techniques employing, for example, vectors and host cells, and, for example, heterologous secretory leader sequences. Also disclosed are methods for using such polypeptides and modulators thereof for the treatment of diseases, including cancer, immune diseases, infectious diseases, and ischemic diseases.



WO 2005/082934 A3